Articles by Tu My To, PhD, MPH
Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous Rituximab
ByEsther Drill, DrPH,Annie Qiu, BA,Sheila Shapouri, PharmD, MS,Tu My To, PhD, MPH,Arliene Ravelo, MPH,Jake Schade, BA,Keith Dawson, DNP, MS,Matthew J. Matasar, MD Rituximab-subcutaneously is associated with significantly reduced chair time vs rituximab-intravenously in a US oncology setting. Widespread adoption would be expected to improve practice efficiency and patient access to care, and to reduce health care resource burden.
